Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies.

AIDS. 1995 Aug;9(8):867-74. Unique Identifier : AIDSLINE MED/96014959
D'Souza MP; Milman G; Bradac JA; McPhee D; Hanson CV; Hendry RM; Division of AIDS, National Institute of Allergy and Infectious; Diseases, National Institutes of Health, Bethesda, Maryland; 20892, USA.

Abstract: OBJECTIVE: To evaluate human monoclonal antibodies (MAb) for neutralizing activity against primary HIV-1 isolates in peripheral blood mononuclear cells. DESIGN: Neutralization activity data were obtained from 11 laboratories on a coded panel consisting of six human MAb to HIV envelope V3, CD4-binding region or gp41. Hyperimmune globulin against HIV-1 and normal human immunoglobulin G were supplied as controls. Each laboratory received pre-titered virus for use in the studies. METHODS: Each laboratory measured neutralization of the MAb against laboratory strain HIVMN, genomic clone HIVJR-CSF, two subtype B and one subtype D primary isolates. RESULTS: The titers of the centrally supplied virus stocks as determined by re-titration or back-titration varied among laboratories and were generally 10-100-fold less than provided. The neutralizing activity of each MAb varied by as much as a 1000-fold among laboratories. These differences may result from varying sensitivity in neutralization assay protocols and the differing susceptibility of primary cells to infection with HIV-1. CONCLUSIONS: To consolidate the data from multiple laboratories, the neutralization titers were compared by classifying antibodies as neutralizing if the antibody concentration for 50% virus inhibition was < or = 10 micrograms/ml. By this criterion, the CD4-binding region and gp41 MAb neutralized all four subtype B viruses and the subtype D isolate in a few of the laboratories. The V3 MAb neutralized only HIVMN and the closely related HIVJR-CSF viruses.

Keywords: *Antibodies, Monoclonal Antigens, CD4/IMMUNOLOGY Comparative Study Gene Products, env/*IMMUNOLOGY Human *HIV Antibodies HIV Envelope Protein gp120/IMMUNOLOGY HIV Envelope Protein gp41/IMMUNOLOGY HIV-1/CLASSIFICATION/*IMMUNOLOGY/ISOLATION & PURIF In Vitro Leukocytes, Mononuclear/VIROLOGY Neutralization Tests Peptide Fragments/IMMUNOLOGY Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. JOURNAL ARTICLE
960228
M9621070

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .